Products
Comprehensive catalog of pharmaceutical solutions. Browse categories and send inquiries directly.
All Products (882)
| Molecule | Drug Class / Mechanism | Oncology Type | Inquiry | |
|---|---|---|---|---|
Elimusertib |
DNA Damage Response Inhibitor | Solid Tumour | ||
|
Molecule
Elimusertib
Therapeutic Category
Targeted Therapy (Investigational)
Oncology Type
Solid Tumour
Drug Class / Mechanism
DNA Damage Response Inhibitor |
||||
Emavusertib |
IRAK4 Kinase Inhibitor | Hematologic | ||
|
Molecule
Emavusertib
Therapeutic Category
Targeted Therapy (Investigational)
Oncology Type
Hematologic
Drug Class / Mechanism
IRAK4 Kinase Inhibitor |
||||
Enavatuzumab |
Investigational Monoclonal / ADC Agent | Solid Tumour | ||
|
Molecule
Enavatuzumab
Therapeutic Category
Targeted Therapy (Investigational Antibody / ADC)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Investigational Monoclonal / ADC Agent |
||||
Enmd-2076 |
Polo-Like / Aurora Kinase Inhibitor | Both (Solid & Hematologic) | ||
|
Molecule
Enmd-2076
Therapeutic Category
Targeted Therapy (Investigational)
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
Polo-Like / Aurora Kinase Inhibitor |
||||
EOS-448 (Belrestotug) |
TIGIT Inhibitor | Solid Tumour | ||
|
Molecule
EOS-448 (Belrestotug)
Therapeutic Category
Immunotherapy (Investigational Checkpoint)
Oncology Type
Solid Tumour
Drug Class / Mechanism
TIGIT Inhibitor |
||||
Epacadostat |
Metabolic Pathway Inhibitor (IDO/STAT3/Glutaminase) | Solid Tumour | ||
|
Molecule
Epacadostat
Therapeutic Category
Targeted Therapy (Investigational)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Metabolic Pathway Inhibitor (IDO/STAT3/Glutaminase) |
||||
Epratuzumab |
Investigational Monoclonal / ADC Agent | Solid Tumour | ||
|
Molecule
Epratuzumab
Therapeutic Category
Targeted Therapy (Investigational Antibody / ADC)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Investigational Monoclonal / ADC Agent |
||||
Etentamig |
Bispecific T-Cell Engager, BCMA x CD3 | Hematologic (Multiple Myeloma) | ||
|
Molecule
Etentamig
Therapeutic Category
Immunotherapy (Investigational)
Oncology Type
Hematologic (Multiple Myeloma)
Drug Class / Mechanism
Bispecific T-Cell Engager, BCMA x CD3 |
||||
Etigilimab |
TIM-3 / LAG-3 / TIGIT Inhibitor | Both (Solid & Hematologic) | ||
|
Molecule
Etigilimab
Therapeutic Category
Immunotherapy (Investigational Checkpoint)
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
TIM-3 / LAG-3 / TIGIT Inhibitor |
||||
Evorpacept |
CD47 (Macrophage Checkpoint) Inhibitor | Hematologic | ||
|
Molecule
Evorpacept
Therapeutic Category
Immunotherapy (Investigational)
Oncology Type
Hematologic
Drug Class / Mechanism
CD47 (Macrophage Checkpoint) Inhibitor |
||||
Farletuzumab |
Investigational Monoclonal / ADC Agent | Solid Tumour | ||
|
Molecule
Farletuzumab
Therapeutic Category
Targeted Therapy (Investigational Antibody / ADC)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Investigational Monoclonal / ADC Agent |
||||
Favezelimab |
TIM-3 / LAG-3 / TIGIT Inhibitor | Both (Solid & Hematologic) | ||
|
Molecule
Favezelimab
Therapeutic Category
Immunotherapy (Investigational Checkpoint)
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
TIM-3 / LAG-3 / TIGIT Inhibitor |
||||
ElimusertibTargeted Therapy (Investigational) |
|
|
Therapeutic Category
Targeted Therapy (Investigational)
Oncology Type
Solid Tumour
Drug Class / Mechanism
DNA Damage Response Inhibitor |
|
EmavusertibTargeted Therapy (Investigational) |
|
|
Therapeutic Category
Targeted Therapy (Investigational)
Oncology Type
Hematologic
Drug Class / Mechanism
IRAK4 Kinase Inhibitor |
|
EnavatuzumabTargeted Therapy (Investigational Antibody / ADC) |
|
|
Therapeutic Category
Targeted Therapy (Investigational Antibody / ADC)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Investigational Monoclonal / ADC Agent |
|
Enmd-2076Targeted Therapy (Investigational) |
|
|
Therapeutic Category
Targeted Therapy (Investigational)
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
Polo-Like / Aurora Kinase Inhibitor |
|
EOS-448 (Belrestotug)Immunotherapy (Investigational Checkpoint) |
|
|
Therapeutic Category
Immunotherapy (Investigational Checkpoint)
Oncology Type
Solid Tumour
Drug Class / Mechanism
TIGIT Inhibitor |
|
EpacadostatTargeted Therapy (Investigational) |
|
|
Therapeutic Category
Targeted Therapy (Investigational)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Metabolic Pathway Inhibitor (IDO/STAT3/Glutaminase) |
|
EpratuzumabTargeted Therapy (Investigational Antibody / ADC) |
|
|
Therapeutic Category
Targeted Therapy (Investigational Antibody / ADC)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Investigational Monoclonal / ADC Agent |
|
EtentamigImmunotherapy (Investigational) |
|
|
Therapeutic Category
Immunotherapy (Investigational)
Oncology Type
Hematologic (Multiple Myeloma)
Drug Class / Mechanism
Bispecific T-Cell Engager, BCMA x CD3 |
|
EtigilimabImmunotherapy (Investigational Checkpoint) |
|
|
Therapeutic Category
Immunotherapy (Investigational Checkpoint)
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
TIM-3 / LAG-3 / TIGIT Inhibitor |
|
EvorpaceptImmunotherapy (Investigational) |
|
|
Therapeutic Category
Immunotherapy (Investigational)
Oncology Type
Hematologic
Drug Class / Mechanism
CD47 (Macrophage Checkpoint) Inhibitor |
|
FarletuzumabTargeted Therapy (Investigational Antibody / ADC) |
|
|
Therapeutic Category
Targeted Therapy (Investigational Antibody / ADC)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Investigational Monoclonal / ADC Agent |
|
FavezelimabImmunotherapy (Investigational Checkpoint) |
|
|
Therapeutic Category
Immunotherapy (Investigational Checkpoint)
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
TIM-3 / LAG-3 / TIGIT Inhibitor |
|